Ivf outcomes in brca carriers with and without addition of letrozole to stimulation

Women with BRCA 1/2 mutations are commonly referred to reproductive endocrinologists to discuss fertility preservation options prior to ovarian and breast cancer risk reducing surgery. Researchers remain divided about whether BRCA carriers might be predisposed to decreased ovarian reserve and accelerated ovarian aging compared to noncarriers, and debate optimal stimulation dosage and protocols.1 The aromatase inhibitor letrozole is commonly used during controlled ovarian stimulation (COH) of breast cancer patients to minimize circulating Estradiol levels, but it is unclear whether its use negatively affects stimulation response, fertilization, and embryo quality.